Jounce Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch JNCE and buy or sell other stocks, ETFs, and their options commission-free!About JNCE
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors.
CEOKevin C. Tang
CEOKevin C. Tang
Employees—
Employees—
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2013
Founded2013
Employees—
Employees—
JNCE Key Statistics
Market cap98.95M
Market cap98.95M
Price-Earnings ratio-1.91
Price-Earnings ratio-1.91
Dividend yield—
Dividend yield—
Average volume2.01M
Average volume2.01M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$5.87
52 Week high$5.87
52 Week low$0.5773
52 Week low$0.5773
Stock Snapshot
With a market cap of 98.95M, Jounce Therapeutics(JNCE) trades at $1.88. The stock has a price-to-earnings ratio of -1.91.
On 2025-12-17, Jounce Therapeutics(JNCE) stock opened at —, reached a high of —, and a low of —.
The Jounce Therapeutics(JNCE)'s current trading volume is 0, compared to an average daily volume of 2.01M.
During the past year, Jounce Therapeutics(JNCE) stock moved between $0.58 at its lowest and $5.87 at its peak.
During the past year, Jounce Therapeutics(JNCE) stock moved between $0.58 at its lowest and $5.87 at its peak.
People also own
Based on the portfolios of people who own JNCE. This list is generated using Robinhood data, and it’s not a recommendation.